In this blog from Prof. Peter Schueler, he explores how biomarker innovation is accelerating progress in Alzheimer’s, Parkinson’s, and other CNS trials - bringing new precision, speed, and clarity to a historically chall...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Regulatory strategy reimagined: Three trends accelerating drug development
The regulatory landscape is being rewritten. The future belongs to those who anticipate, adapt and act with purpose. In this article we look at 3 macro trends that are redefining regulatory strategy.
-
Harmonising global approaches to transformative theranostics
This article explores the landscape, regulatory considerations, infrastructural and operational requirements along with future directions for expanding Radiopharmaceuticals and Theranostics therapies into clinical settings.
-
Multidrug-Resistant Infections Necessitate Bacteriophage Treatment: Can We Get There in Time?
As antibiotic resistance surges globally, bacteriophage therapy is emerging as a promising alternative for treating multidrug-resistant infections. To scale this life-saving approach, investment in phage development, clinical trials, and diagnostic infrastructure is urgently needed.
-
CRO reforms: Tilting scale towards accelerated growth and transparency
The article, featuring commentary from Nagalakshmi Shetty, highlights how India's clinical research sector is rapidly expanding. Regulatory reforms like the Central Drugs Standard Control Organisation's NDCR (Amendment) Rules 2024, mandatory CRO registration and digitised portals are boosting transparency, shortening approval timelines and positioning India as a global hub for clinical trials.
-
Keeping it real
In this PharmaTimes article, Nagalakshmi Shetty explores how clinical data science is evolving from traditional management toward intelligent, risk-based, patient-centric research frameworks.
-
Navigating, manufacturing, infrastructure and regulatory hurdles in CAR T-Cell therapy growth
Explore how industry leaders are overcoming manufacturing and regulatory hurdles to scale CAR-T cell therapies across Asia-Pacific.
-
ICON recognised as one of World's top companies for women
ICON have been included in Forbes' list of only 400 global companies. Based on a survey of approximately 120,000 women in more than 36 countries, positions were awarded to companies that have been identified as top performers in promoting gender equality and supporting women in the workplace.
-
Precision medicine meets machine learning: AI and oncology biomarkers
AI is redefining oncology biomarker discovery, unlocking new precision in patient selection and trial design. Explore how this evolving technology is shaping the future of cancer drug development.
-
Smarter starts, stronger trials: How data is driving faster site activation
Feasibility, site selection and study startup are among the most complex areas of clinical development, yet they remain stubbornly inefficient. ICON’s Brian Mallon explores how sponsors and CROs are leveraging AI, predictive analytics and integrated data environments for faster, more predictable trial delivery and stronger site partnerships. Read the full article.
-
Clinical trials - Keeping pace with shifting drug development paradigms for multi-indication therapies
In this article, learn how sponsors can drive multi-indication success through strategic trial design, early cross-functional planning, and evidence-driven development.
